Hollywood Media Corp. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013
April 07, 2014 at 04:31 pm EDT
Share
Hollywood Media Corp. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company announced net revenues of $101,306 compared to $187,256 for the same period a year ago. Loss from operations was $1,052,247 compared to $2,167,497 for the same period a year ago. Loss from continuing operations before income taxes was $1,652,415 compared to income of $983,061 for the same period a year ago. Loss from continuing operations was $1,626,532 or $0.07 per basic and diluted share compared to income from continuing operations of $4,810,879 or $0.21 per basic and diluted share for the same period a year ago. Net loss was $1,626,532 or $0.07 per basic and diluted share compared to net income of $11,834,665 or $0.51 per basic and diluted share for the same period a year ago.
For the full year, the company announced net revenues of $424,751 compared to $616,338 for the same period a year ago. Loss from operations was $4,887,354 compared to $5,702,427 for the same period a year ago. Income from continuing operations before income taxes was $6,453,813 compared to loss of $4,407,997 for the same period a year ago. Income from continuing operations was $6,252,848 or $0.28 per basic and diluted share compared to $918,303 or $0.04 per basic and diluted share for the same period a year ago. Net income was $6,252,848 or $0.28 per basic and diluted share compared to $10,409,564 or $0.45 per basic and diluted share for the same period a year ago.
NovelStem International Corp. is a development-stage biotechnology holding company focused on stem cell-based technology. The Company's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem focuses on the development and commercialization of diagnostic technology that can predict patientsâ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. NetCo is a media business interest which owns Net Force, a book publishing franchise.